The fold variant BM4 is beneficial in a therapeutic Bet v 1 mouse model.

Biomed Res Int · 2013 · PMC3794650 · PMID 24175303

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Treatment with BM4 Was Able to Shift an Allergic Immune Response Analyses of splenocyte supernatants of either actively or sham treated animals, which were re-stimulated with Bet v 1, revealed a clear trend showing that BM4 treatment led to suppression of the TH2 cytokines IL-5 and IL-13 accompanied by an upregulation of IFN- γ and IL-10.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.